APRE - Aprea Therapeutics Receives Breakthrough Therapy Designation for APR-246
Aprea Therapeutics (NASDAQ: APRE) announced today that the Food and Drug Administration has given its breakthrough therapy designation to the company's lead drug candidate, APR-246. It is being tested in a cocktail with Azacitidine (a type of chemotherapy) to treat myelodysplastic syndrome (MDS), a condition that often progresses to leukemia.
APR-246 is designed to help patients who have a genetic mutation in tp53, a key cancer-suppressing gene. This gene provides cells with the instructions for producing a protein (P53) that keeps cell division in check, thus suppressing cancers in the human body. When the gene mutates and stops working, cancer proliferates. P53 is the most common mutated gene in human cancers, occurring in approximately 50% of all tumors.
Image source: Getty Images